bs-10420R-Cy3 [Conjugated Primary Antibody]
Nemo-like kinase Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Nemo-like kinase

Immunogen Range: 101-200/527


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human Nemo-like kinase

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Nemo-like kinase (NLK) plays a role in cell fate determination and is required for differentiation of bone marrow stromal cells. It acts downstream of MAP3K7 and HIPK2 to negatively regulate the canonical Wnt/beta-catenin signaling pathway and the phosphorylation and destruction of the MYB transcription factor. It may suppress a wide range of transcription factors by phosphorylation of the coactivator, CREBBP. (referenced from swissprot)

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 58


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Cow
Sheep
Chicken
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Sara Fernndez. et al. BET inhibitors induce NF-B and E2F downregulation in Hodgkin and ReedCSternberg cells. EXP CELL RES. 2023 Sep;430:113718Read more>>